NEW FACTORIES, STABILIZING INDUSTRIAL CHAIN

"China is a stabilizer in the global supply chain," Megarbane said, noting that China's competitive advantages in the global supply chain are not just in cost and scale, but more in market potential, product quality and innovation capacity.

This view was echoed by U.S. electric carmaker Tesla, which began accepting orders for made-in-China Model Y SUVs on its China official website earlier this week. The production of the pre-ordered cars will begin as early as next year.

It has been less than eight months since the U.S. electric carmaker announced the launch of a project to manufacture Model Y vehicles in its Shanghai gigafactory, its first overseas plant outside the United States, in early January.

Tesla's founder Elon Musk expressed gratitude for the hard work of the Chinese team during his keynote speech at the opening ceremony of the World Artificial Intelligence Conference in July.

Tao Lin, vice president for external affairs at Tesla China, said the expansion of the Shanghai gigafactory is expected to be finished by year-end, and the mass production of made-in-China Model Ys will start in the first quarter of 2021.

The smooth and quick recovery of production in China has injected confidence into foreign companies.

Statistics showed that in the first half of this year, the actual amount of utilized foreign capital in Shanghai increased by 5.4 percent year on year, with 26 regional headquarters of multinationals newly set up in the city.

After participating in the second CIIE last November, Israeli hi-tech company Watergen, which produces high-quality drinking water from air, has set up its China headquarters in Shanghai and started investing and building factories in the Yangtze River Delta region.

"We are very optimistic about the prospects of the Chinese market," said Ivan Melnikov, Watergen's chief representative in China. The tech firm has already signed up for this year's CIIE.

NEW R&D CENTERS, GLOBAL INNOVATION HUB

In just five months, a salted egg yolk and cheese-flavored ice cream product has gone from nothing more than a bold idea to a bestseller in China.

It was one of the innovative products developed by the Fonterra-ACC Shanghai Innovation Center, jointly set up by New Zealand-based multinational dairy cooperative Fonterra and food quality certification firm Anchor Center for R&D and Certification (ACC Shanghai).

If the innovation process had taken place in R&D centers overseas, it would have been about three years before the product could enter the Chinese market, according to Paul Washer, chief financial officer of Fonterra for Greater China.

The center was officially put into use in mid-August after several months of trial operation, a fresh move demonstrating Fonterra's confidence in the Chinese market and its long-term commitment to cultivating the market.

"China is one of the fastest-changing food and beverage markets in the world. Only with higher innovation efficiency and faster production of new products can we better adapt to the Chinese market," Washer said.

As an extension of Fonterra's research capabilities worldwide, the Shanghai facility is designed for product development, sensory assessments, consumer science, nutrition science and packaging, among other functions.

"As one of the world's largest dairy companies, Fonterra is very optimistic about China's future," he added, noting that China is not only a consumer market, but also a critical source of innovation and an important part of the global industrial value chain.

In the first half of this year, a total of 10 foreign-funded R&D centers were set up in Shanghai. Boehringer Ingelheim, the world's leading pharmaceutical company, announced in March this year it would set up its first overseas BI X digital lab in Shanghai. The company also launched an external innovation hub in Shanghai this July.

"China has strategic importance to the company, and we have a long-term commitment to improving health outcomes and addressing unmet medical needs in China," said Felix Gutsche, chairman and CEO of Boehringer Ingelheim Greater China, adding that the company is investing 451 million euros in China over the next five years.

Cao Lei, deputy director of the commission of commerce in the Shanghai Pudong New Area, said foreign enterprises have been investing in R&D centers despite the epidemic, which shows China's prominence in the global innovation landscape.